The short version of RP-HPLC fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-07-06. Anything still debated is marked as such rather than presented as settled.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
| Property | Value | Notes |
|---|---|---|
| Primary research area | Obesity and metabolic regulation | Studied in cell, animal, and human models |
| Highest reported trial phase | Phase II | Public summaries describe mixed results |
| Common route in trials | Subcutaneous injection | Typical for peptide therapeutics |
| Regulatory example | 2013 Australian anti-doping review | Classification was debated at the time |
| Approval status | Not approved as a human medicine | Status can change by jurisdiction |
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
== Company history == The company traces its roots to William Lines, Inc., which began as a shipping business founded by William Chiongbian on December 13, 1945, in Cebu City. He named one of its first vessels, the MV Victoriano, after his father; the ship made its maiden voyage serving the routes from Cebu to Tagbilaran, Bohol, and Siquijor, then to Plaridel and Ozamiz. The company was later incorporated on May 26, 1949. From the 1970s to the 1990s, the company introduced several flagship vessels, including MV Cebu City (1972), MV Doña Virginia (1980), and MV Sugbu (1989), and grew to become one of the largest shipping companies in the Philippines during that period. In the 1990s, William Lines introduced the Mabuhay Series, comprising the company's largest and most luxurious vessels, designed to compete with rival fleets, including Sulpicio Lines and Aboitiz's SuperFerry ships. The first ship of the series, the Wilines Mabuhay 1, was acquired from Japan and was part of the well-known Sunflower series of vessels. Subsequently, William Lines added more ships to the Mabuhay Series, including Mabuhay 2, 3, 5, and 6. In December 1995, William Lines acquired the assets of Gothong Lines and Aboitiz Shipping Corporation through a ₱5.68 billion share-swap deal, issuing new William Lines shares to the two companies in exchange for their shipping properties. The merger consolidated the operations of the three shipping firms, forming William, Gothong and Aboitiz Inc. (WG&A), which became the largest domestic shipping company in the Philippines.
=== Environmental controls === Many libraries monitor a building's atmosphere through the use of HVAC systems. These built-in ventilation systems help to combat mold growth that occurs as a result of relative humidity levels greater than 65% and temperature greater than 70 °F (21 °C), as well poor air circulation. Proper use and monitoring of HVAC systems can help to prevent mold problems before they occur. Air ventilation removes existing mold spores from the air and keeps the atmosphere relatively dry and cool. Effective HVAC systems have a good system design and the ability to provide environmental control over entire building areas. Proper maintenance of equipment also lowers the chances that issues will arise due to system outages . At 70 °F (21 °C) and 50% relative humidity, the equilibrium moisture content of the environment would be 9.2%, low enough to prevent mold growth. However, proper air flow and air exchange is required to effectively disrupt the boundary layers of air around room contents, which can have high water vapor levels within the surrounding dry air and promote mold amplification.
"Immigrant Women in the United States: A Demographic Portrait" Jill Esbenshade (Summer 2007). "Division and Dislocation: Regulating Immigration through Local Housing Ordinances". American Immigration Council Jeffrey S. Passel & Roberto Suro (September 2005). "Rise, Peak and Decline: Trends in U.S. Immigration" Archived 31 December 2007 at the Wayback Machine. Pew Hispanic Center Jeffrey S. Passel (March 2005). "Estimates of the Size and Characteristics of the Undocumented Population" Archived 31 December 2007 at the Wayback Machine. Pew Hispanic Center Jeffrey S. Passel (March 2007). "Growing Share of Immigrants Choosing Naturalization" Archived 28 December 2007 at the Wayback Machine. Pew Hispanic Center This article incorporates public domain material from Report for Congress: Agriculture: A Glossary of Terms, Programs, and Laws, 2005 Edition (PDF). Congressional Research Service. UNCTAD's Classification of Non-Tariff Measures (2012) report
Sources: en.wikipedia.org
=== Prokaryotic === Although sterol biosynthesis is rare in prokaryotes, certain bacteria, including Methylococcus capsulatus, specific methanotrophs, myxobacteria, and the planctomycete Gemmata obscuriglobus, are capable of producing sterols. In G. obscuriglobus, sterols are essential for cell viability, but their roles in other bacteria remain poorly understood. Prokaryotic sterol synthesis involves the tetracyclic steroid framework, as found in myxobacteria, as well as hopanoids, pentacyclic lipids that regulate bacterial membrane functions. These sterol biosynthetic pathways may have originated in bacteria or been transferred from eukaryotes. Sterol synthesis depends on two key enzymes: squalene monooxygenase and oxidosqualene cyclase. Phylogenetic analyses of oxidosqualene cyclase (Osc) suggest that some bacterial Osc genes may have been acquired via horizontal gene transfer from eukaryotes, as certain bacterial Osc proteins closely resemble their eukaryotic homologs.
Neo (born as Thomas A. Anderson, also known as The One) is a fictional character and the protagonist of The Matrix franchise, created by the Wachowskis. He was portrayed as a cybercriminal and computer programmer by Keanu Reeves in the films, as well as having a cameo in The Animatrix short film Kid's Story. Andrew Bowen provided Neo's voice in The Matrix: Path of Neo. In 2021, Reeves reprised his role in The Matrix Resurrections with what Vulture calls "his signature John Wick look". In 2008, Neo was selected by Empire as the 68th Greatest Movie Character of All Time. "Neo" is also an anagram of "one", a reference to his destiny of being The One who would bring peace. There are claims that a nightclub in Chicago inspired the name of the character. Neo is considered to be a superhero.
== Operations == EFLM has an Executive Board and a range of committees for: science, education and training, quality and regulations, communication and professional representation. Each committee has working groups with a Chair and three full members, there is also a Young Scientist member and they may also have corresponding members, but only one member form each country is permitted. The Science Committee develops collaborative science in Laboratory Medicine between member organisations or individuals and guidelines to set standards of practice to assist member societies in providing quality patient care. The output of the scientific working groups is scientific papers and presentations which contribute to the science of laboratory medicine internationally; a list of publications can be found on the EFLM web-site (link below). Typically publications are peer-reviewed and published in the journal Clinical Chemistry and Laboratory Medicine. The Working Groups are overseen by the Chair of the Science Committee and their activities reviewed annually; scientific and clinically relevant output determine whether they continue. The Education and Training Committee runs educational activities particularly for trainees and those required to develop new skills as well as running scientific and clinical conferences, webinars, etc. The major Congress is Euromedlab held in conjunction with the IFCC, meetings are selected from bids by member societies at the annual General Meeting.
Sources: en.wikipedia.org
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.
It became prominent during a 2013 Australian sports investigation that examined whether it was a prohibited growth-hormone-related substance. Subsequent interpretations and list updates have varied, so current rules should be checked directly.
Published summaries generally report limited or inconsistent weight-loss effects, and complete trial data are not widely available. The studies were not sufficient to establish it as an effective obesity treatment.
Lyophilized powder is commonly stored at −20 °C or below, protected from light and moisture. Reconstituted solutions are typically kept refrigerated and used within a limited period.